Aki Soudunsaari
CEO @ Springvest
Helsinki, Finland
Aki Soudunsaari is a seed investor at Springvest in Helsinki focused on Pharmaceutical and Medical. Aki Soudunsaari - Co-founder & Strategy, Board Member @ Naava
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Aki Soudunsaari invests in
Stages Aki Soudunsaari invests in
Countries Aki Soudunsaari invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Pharmaceutical 2 (100%)
- Medical 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Precision Medicine 1 (50%)
Stage
- Seed 1 (50%)
- Venture - Series Unknown 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivityreaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society. | $31.4M / Venture - Series Unknown / Oct 12, 2026 | ||
| CurifyLabs develops technology for the automated compounding of personalized medicines used in pharmacies and hospitals. Its platform combines compounding hardware, software, validated excipient bases, integrated quality control, and digital documentation to support the preparation of non-sterile medications through standardized workflows. Thecompany also provides formulation libraries and tools that enable pharmacists to create and produce patient-specific dosage forms while maintaining traceability and consistency throughout the compounding process. Its solutions are used to support personalized medication preparation across a range of healthcare settings. | $7.6M / Seed |
About Springvest
Springvest is a listed growth equity investor connecting Finnish technology companies with both domestic and international capital. We typically raise €5–12 million rounds from our Finnish investor base and lead larger rounds of up to €50 million together with international co-investors. We remain a committed minority shareholder in every company we back.
Springvest Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Aki Soudunsaari
CEO
|
|||
|
Jouni Mäkelä
Investment Director
|
|||
|
Markku Jussila
Co-Founder & Director
|
|||
Päivi Malinen
Chief Executive Officer
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Aki Soudunsaari invest in?
Aki Soudunsaari invests primarily in Pharmaceutical, Medical and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Aki Soudunsaari?
Public channels for Aki Soudunsaari include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Aki Soudunsaari last invest?
The most recent investment recorded for Aki Soudunsaari closed in Oct 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
